LeonaBio, Inc. LONA
We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis ("ALS"), with the goal of improving patients' lives.
Following a review of potential therapeutic and business opportunities, we acquired rights to a promising late-stage asset, lasofoxifene, for the potential treatment of ESR1-mutated ("mESR1") metastatic breast cancer in December 2025. This late-stage program has generated promising clinical data and we believe it represents a unique and exciting opportunity to diversify our pipeline. We believe this program fits well with our later-stage clinical development experience, and complements our in-house asset, ATH-1105, a Phase-2 ready program for the potential treatment of ALS.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $17.5M | $70.7M | $93.8M | $61.5M | $42.8M | $13.3M | $3.8M | — |
| SG&A | $16.7M | $26.1M | $33.3M | $32.6M | $21.2M | $6.7M | $1.7M | — |
| Total operating expenses | $102.3M | $100.9M | $125.5M | $104.0M | $64.0M | $20.0M | $5.4M | — |
| Operating income | -$102.3M | -$100.9M | -$125.5M | -$104.0M | -$64.0M | -$20.0M | -$5.4M | — |
| Interest expense | — | — | — | — | $3.0K | $367.0K | $346.0K | — |
| Pre-tax income | -$106.0M | — | — | — | — | -$20.0M | -$5.2M | — |
| Income tax | $0 | — | — | — | — | — | — | — |
| Net income | -$106.0M | -$97.0M | -$117.7M | -$95.6M | -$54.9M | -$20.0M | -$5.2M | — |
| EPS, basic | -24.70 | -25.19 | -3.09 | -2.53 | -1.49 | — | — | — |
| EPS, diluted | -24.70 | -25.19 | -3.09 | -2.53 | -1.49 | -1.67 | -1.45 | — |
| Shares, diluted (wtd. avg.) | 4.3M | 3.8M | 38.0M | 37.7M | 36.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $69.3M | $48.4M | $90.6M | $96.0M | $110.5M | $60.6M | $2.1M | — |
| Short-term investments | $19.1M | $2.8M | $56.8M | $104.4M | $143.2M | $124.1M | — | — |
| Total current assets | $89.5M | $54.8M | $154.7M | $207.5M | $260.8M | $192.3M | $2.2M | — |
| Property, plant and equipment | $1.5M | $2.4M | $3.4M | $4.1M | $3.8M | $2.6M | — | — |
| Total assets | $92.2M | $58.8M | $160.2M | $258.2M | $332.0M | $279.6M | $2.2M | — |
| Accounts payable | $4.6M | $319.0K | $129.0K | $2.5M | $567.0K | $1.2M | $421.0K | — |
| Total current liabilities | $47.5M | $13.1M | $28.8M | $21.4M | $9.3M | $4.4M | $1.3M | — |
| Total liabilities | $64.4M | $13.9M | $30.1M | $23.0M | $10.9M | $5.3M | $4.9M | — |
| Retained earnings | -$511.8M | -$406.1M | -$309.2M | -$191.5M | -$95.9M | -$41.0M | -$21.1M | — |
| Total equity | $27.8M | $44.8M | $130.2M | $235.1M | $321.1M | $274.3M | -$19.7M | -$14.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$45.7M | -$97.2M | -$100.8M | -$72.5M | -$43.1M | -$24.1M | -$3.7M | — |
| Depreciation and amortisation | $972.0K | $970.0K | $969.0K | $845.0K | $479.0K | $2.0K | $2.0K | — |
| Stock-based compensation | $6.1M | $11.0M | $10.6M | $10.6M | $4.6M | $633.0K | $253.0K | — |
| Capital expenditure | — | $33.0K | $304.0K | $1.1M | $1.6M | $2.3M | — | — |
| Investing cash flow | -$15.9M | $54.8M | $95.1M | $57.7M | -$4.1M | -$210.1M | $1.5M | — |
| Financing cash flow | $82.5M | $194.0K | $493.0K | $654.0K | $97.1M | $292.8M | $946.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-216742.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$5.2M | -$20.0M | -$54.9M | -$95.6M | -$117.7M | -$97.0M | -$106.0M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $240.38B | 31.2x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $196.77B | 23.4x | 2.4% |
| MRNA | Moderna, Inc. | $79.39B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $39.42B | — | — |
| BIIB | BIOGEN INC. | $37.24B | 28.7x | 2.2% |
| EXEL | EXELIXIS, INC. | $16.13B | 23.4x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.83B | 31.2x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.53B | 50.0x | 37.6% |